{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T11:18:56Z","timestamp":1696331936089},"reference-count":32,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2014,7,9]],"date-time":"2014-07-09T00:00:00Z","timestamp":1404864000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Viral Hepatitis"],"published-print":{"date-parts":[[2014,11]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>The ongoing epidemic of acute hepatitis C (<jats:styled-content style=\"fixed-case\">AHC<\/jats:styled-content>) infection among <jats:styled-content style=\"fixed-case\">MSM<\/jats:styled-content> highlights the need to identify factors allowing for optimal treatment outcome in <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content> co\u2010infected individuals. Cohort study of 105 <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content>\u2010infected patients with <jats:styled-content style=\"fixed-case\">AHC<\/jats:styled-content> infection from five centres in two <jats:styled-content style=\"fixed-case\">E<\/jats:styled-content>uropean countries was carried out. Choice of treatment with peg<jats:styled-content style=\"fixed-case\">IFN<\/jats:styled-content>\u2010alfa alone (group 1; <jats:italic>n<\/jats:italic>\u00a0=\u00a036) or peg<jats:styled-content style=\"fixed-case\">IFN<\/jats:styled-content>\u2010alfa and ribavirin (<jats:styled-content style=\"fixed-case\">RBV<\/jats:styled-content>) (group 2; <jats:italic>n<\/jats:italic>\u00a0=\u00a069) was at the discretion of the investigator. Outcome was evaluated as <jats:styled-content style=\"fixed-case\">RVR<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">SVR<\/jats:styled-content>. Fisher's exact and <jats:styled-content style=\"fixed-case\">M<\/jats:styled-content>ann <jats:styled-content style=\"fixed-case\">W<\/jats:styled-content>hitney <jats:italic>U<\/jats:italic> tests were used for statistical analysis. All patients were male, median age was 39\u00a0years, main route of transmission <jats:styled-content style=\"fixed-case\">MSM<\/jats:styled-content> (91%). In 69% of patients, clinical signs of acute hepatic infection were missing, dominant <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> genotypes were 1 (64%) and 4 (16%) and mean baseline <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">RNA<\/jats:styled-content> was 3.559.085 <jats:styled-content style=\"fixed-case\">IU<\/jats:styled-content>\/mL. 60% received <jats:styled-content style=\"fixed-case\">HAART<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>4 cell count was 469\/mm<jats:sup>3<\/jats:sup>. Overall <jats:styled-content style=\"fixed-case\">SVR<\/jats:styled-content> rate was 64.8% (68\/105). <jats:styled-content style=\"fixed-case\">SVR<\/jats:styled-content> was reached in 69% of treated patients in group 1 and in 63% of treated patients in group 2 (<jats:italic>P<\/jats:italic>\u00a0=\u00a00.67) while <jats:styled-content style=\"fixed-case\">RVR<\/jats:styled-content> was seen in 61% and 49%, respectively (<jats:italic>P<\/jats:italic>\u00a0=\u00a00.35). Interestingly, by univariate analysis, <jats:styled-content style=\"fixed-case\">SVR<\/jats:styled-content> rates in group 1 were significantly higher in patients initiating therapy within 4\u00a0weeks of <jats:styled-content style=\"fixed-case\">AHC<\/jats:styled-content> diagnosis compared to patients initiating therapy within 5\u201336\u00a0weeks after diagnosis (<jats:italic>P<\/jats:italic>\u00a0=\u00a00.03). Peg<jats:styled-content style=\"fixed-case\">IFN<\/jats:styled-content>\u2010alfa alone or in combination with ribavirin results in similar response rates in <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content>\u2010infected patients with <jats:styled-content style=\"fixed-case\">AHC<\/jats:styled-content>. In particular, when treatment is initiated within 4\u00a0weeks of diagnosis, peg<jats:styled-content style=\"fixed-case\">IFN<\/jats:styled-content> mono\u2010therapy might be sufficient to allow for an optimal treatment response.<\/jats:p>","DOI":"10.1111\/jvh.12272","type":"journal-article","created":{"date-parts":[[2014,7,9]],"date-time":"2014-07-09T07:03:30Z","timestamp":1404889410000},"page":"780-785","source":"Crossref","is-referenced-by-count":10,"title":["Peginterferon\u2010alfa mono\u2010therapy in the treatment of acute hepatitis C in <scp>HIV<\/scp>\u2010infection"],"prefix":"10.1111","volume":"21","author":[{"given":"C.","family":"Boesecke","sequence":"first","affiliation":[{"name":"Bonn University Hospital Bonn Germany"},{"name":"German Centre for Infection Research (DZIF) Partner Site Cologne\u2010Bonn Bonn Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"van Assen","sequence":"additional","affiliation":[{"name":"University Medical Center Groningen Groningen the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.\u2010J.","family":"Stellbrink","sequence":"additional","affiliation":[{"name":"ICH Study Center Hamburg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Baumgarten","sequence":"additional","affiliation":[{"name":"Medical Center for Infectious Diseases Berlin Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Ingiliz","sequence":"additional","affiliation":[{"name":"Medical Center for Infectious Diseases Berlin Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. P.","family":"Strassburg","sequence":"additional","affiliation":[{"name":"Bonn University Hospital Bonn Germany"},{"name":"German Centre for Infection Research (DZIF) Partner Site Cologne\u2010Bonn Bonn Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Schwarze\u2010Zander","sequence":"additional","affiliation":[{"name":"Bonn University Hospital Bonn Germany"},{"name":"German Centre for Infection Research (DZIF) Partner Site Cologne\u2010Bonn Bonn Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.\u2010C.","family":"Wasmuth","sequence":"additional","affiliation":[{"name":"Bonn University Hospital Bonn Germany"},{"name":"German Centre for Infection Research (DZIF) Partner Site Cologne\u2010Bonn Bonn Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. I. M.","family":"Hoepelman","sequence":"additional","affiliation":[{"name":"University Medical Center Utrecht (UMCU) Utrecht the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. K.","family":"Rockstroh","sequence":"additional","affiliation":[{"name":"Bonn University Hospital Bonn Germany"},{"name":"German Centre for Infection Research (DZIF) Partner Site Cologne\u2010Bonn Bonn Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. E.","family":"Arends","sequence":"additional","affiliation":[{"name":"University Medical Center Utrecht (UMCU) Utrecht the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,7,9]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1136\/sti.2003.008532"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.2807\/esm.10.05.00535-en"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/sti.2007.027334"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1086\/431486"},{"issue":"47","key":"e_1_2_7_6_1","first-page":"19042","article-title":"Setting up an enhanced surveillance of newly acquired hepatitis C infection in men who have sex with men: a pilot in London and South East region of England","volume":"13","author":"Ruf M","year":"2008","journal-title":"Euro Surveill"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32832e5631"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1086\/600058"},{"key":"e_1_2_7_9_1","unstructured":"GallottaG GaliL De BonaAet\u00a0al.Acute hepatitis C virus in HIV co\u2010infected men who have sex with men: Milan 1996\u20132007. In: 4th International HIV and Hepatitis Co\u2010infection; Madrid Spain; 2008; abstract 47."},{"key":"e_1_2_7_10_1","unstructured":"LarsenC AlricL AuperinIet\u00a0al.Acute hepatitis C in HIV\u2010infected men who have sex with men in France in 2006 and 2007. In: 58th Annual Meeting of the American Association for the Study of the Liver Boston USA; 2007; abstract 894."},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2010.01392.x"},{"issue":"39","key":"e_1_2_7_12_1","doi-asserted-by":"crossref","first-page":"19673","DOI":"10.2807\/ese.15.39.19673-en","article-title":"Hepatitis C virus infection in HIV\u2010infected men who have sex with men: sustained rising incidence in Antwerp, Belgium, 2001\u20102009","volume":"15","author":"Bottieau E","year":"2010","journal-title":"Euro Surveill"},{"key":"e_1_2_7_13_1","unstructured":"FiererD FishmanS UrielAet\u00a0al.Characterization of an outbreak of acute HCV infection in HIV\u2010infected men in New York city. In: 16th Conference on Retroviruses and Opportunistic Infections; Montreal Canada; 2009; abstract 802."},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.qai.0000191281.77954.27"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1086\/596770"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1136\/sextrans-2012-050566"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.idc.2012.08.011"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/OLQ.0b013e3181ec9de5"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0017781"},{"issue":"1","key":"e_1_2_7_20_1","first-page":"43","article-title":"Treatment of acute hepatitis C virus infection in HIV+ patients: Dutch recommendations for management","volume":"69","author":"Arends JE","year":"2011","journal-title":"Neth J Med"},{"issue":"4","key":"e_1_2_7_21_1","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/QAD.0b013e328343443b","article-title":"Acute hepatitis C in HIV\u2010infected individuals: recommendations from the European AIDS Treatment Network (NEAT) consensus conference","volume":"25","author":"The European AIDS Treatment Network (NEAT) Acute Hepatitis C Infection Consensus Panel","year":"2011","journal-title":"AIDS"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.qai.0000174930.64145.a9"},{"key":"e_1_2_7_23_1","doi-asserted-by":"crossref","unstructured":"MatthewsG GrebelyJ HellardMet\u00a0al.Differences in early virological decline in individuals treated within the Australian trial in acute HCV suggest a potential benefit for the use of ribavirin. In: 45th Annual Meeting of the European Association for the Study of the Liver (EASL). Vienna Austria; 2010: Abstract O60.","DOI":"10.1016\/S0168-8278(10)60062-1"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3283480144"},{"key":"e_1_2_7_25_1","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1177\/135965350601100817","article-title":"Pegylated interferon\u2010alpha for the treatment of sexually transmitted acute hepatitis C in HIV\u2010infected individuals","volume":"11","author":"Vogel M","year":"2006","journal-title":"Antivir Ther"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP1843"},{"key":"e_1_2_7_27_1","unstructured":"BoeseckeC IngilizP StellbrinkHJet\u00a0al.Ribavirin is needed in addition to pegylated interferon for optimal treatment responses in the treatment of acute HCV genotype 2 and 3 infection in HIV co\u2010infected individuals. 19th Conference on Retroviruses and Opportunistic Infections Seattle U.S.A. 2012 Abstract #Q\u2010133."},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature08309"},{"key":"e_1_2_7_29_1","unstructured":"DeterdingK GrunerNH BuggischPet\u00a0al.Early versus delayed treatment of acute hepatitis C: the German HEP\u2010NET Acute HCV\u2010III study \u2010 a randomized controlled trial. 47th Annual Meeting of the European Association for the Study of the Liver (EASL). Barcelona Spain; 2012.Abstract 48."},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3283553719"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0b013e32834bcbd9"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2004.06.015"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit799"}],"container-title":["Journal of Viral Hepatitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjvh.12272","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjvh.12272","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvh.12272","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T10:39:40Z","timestamp":1696243180000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jvh.12272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,9]]},"references-count":32,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["10.1111\/jvh.12272"],"URL":"https:\/\/doi.org\/10.1111\/jvh.12272","archive":["Portico"],"relation":{},"ISSN":["1352-0504","1365-2893"],"issn-type":[{"value":"1352-0504","type":"print"},{"value":"1365-2893","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,9]]}}}